MedPath

anti-OX40 antibody BMS 986178

Generic Name
anti-OX40 antibody BMS 986178
Drug Type
Biotech
Unique Ingredient Identifier
P9XVH8H2HF

Overview

A macrocyclic peptide (BMS-986189) with activity in binding and functional assays comparable to a PD-L1 antibody.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: May 13, 2025

Medication Report: anti-OX40 antibody BMS 986178

Name: anti-OX40 antibody BMS 986178 Name (English): anti-OX40 antibody BMS 986178 DrugBank ID: DB15773 Type: Biotech

Description: BMS-986178 is a fully human IgG1 agonistic monoclonal antibody that binds with high affinity to the OX40 receptor (CD134; TNFRSF4). OX40 is a co-stimulatory receptor expressed on T-lymphocytes that, upon activation, promotes the proliferation and survival of activated T-cells. BMS-986178 mimics the action of the endogenous OX40 ligand (OX40L), leading to the activation of the OX40 receptor. This activation can induce the proliferation of memory and effector T-lymphocytes and, in the presence of tumor-associated antigens (TAAs), may enhance an immune response against TAA-expressing tumor cells.

Mechanism of Action: As an agonist monoclonal antibody, BMS-986178 selectively binds to and activates the OX40 receptor on T-cells. This activation provides a co-stimulatory signal, promoting T-cell proliferation, differentiation into effector cells, and survival. In the context of cancer, this enhanced T-cell activity can potentially lead to an improved anti-tumor immune response.

Clinical Trials: BMS-986178 has been evaluated in clinical trials, both as a monotherapy and in combination with other immunotherapeutic agents such as nivolumab (anti-PD-1 antibody) and ipilimumab (anti-CTLA-4 antibody), in patients with advanced solid tumors and low-grade B-cell non-Hodgkin lymphomas. These trials have assessed the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and anti-tumor activity of the drug.

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.